Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.40 |
| ▸ | CA9 | Q16790 | 6/20 | 0.40 |
| ▸ | CA12 | O43570 | 5/20 | 0.40 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | BRD4 | O60885 | 2/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.34 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7898409 | 0.88 | CA12 (0.40) | CA2CA9CA12ENPP3CA4 | |
| SCHEMBL4748211 | 0.82 | NPSR1 (0.41) | CA2CA9CA12ENPP3CA4 | |
| SCHEMBL7898133 | 0.79 | CA9 (0.40) | CA2CA9CA12ENPP3CA4 | |
| SCHEMBL7900089 | 0.79 | CA2 (0.46) | CA2CA9CA12CA4CA1 | |
| SCHEMBL7903597 | 0.75 | ALDH1A1 (0.45) | CA2CA9CA12CA1MEN1 | |
| SCHEMBL4748833 | 0.72 | CA12 (0.40) | CA2CA9CA12ENPP3CA4 | |
| SCHEMBL7892625 | 0.69 | BRD4 (0.49) | PKMBRD4MEN1KMT2AALDH1A1 | |
| SCHEMBL4788376 | 0.68 | FLT3 (0.40) | CA2CA9CA12BRD4ALDH1A1 | |
| SCHEMBL7892682 | 0.67 | SYK (0.44) | CA2CA9CA12CA1MEN1 | |
| SCHEMBL4748170 | 0.66 | CA2 (0.46) | CA2CA9CA12CA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221103-A1 | New heterocyclic compounds | ORCHID RESEARCH LABORATORIES LTD. (IN) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221103-A1 | New heterocyclic compounds | LOXL4, CXCR4, LTC4S | CA2 2732/4885CA9 3052/4885CA12 3795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.